Skip to main content

Table 2 Quality of life outcomes from the ATTAIN trial [33]

From: Abatacept in the treatment of rheumatoid arthritis

  Abatacept (mean change from baseline) Placebo (mean change from baseline) P value (abatacept versus placebo)
Physical functioning 5.3 1.2 0.0001
Physical role 6.7 0.8 <0.0001
Pain 8.7 2.2 <0.0001
General health 3.9 0.7 0.0002
Vitality 6.9 1.2 <0.0001
Social functioning 7.4 2.2 <0.0001
Emotional role 6.3 2.0 0.0133
Mental health 4.6 1.1 0.0012
Physical component score 6.5 1.0 <0.0001
Mental component score 5.5 1.7 0.0025
Fatigue VAS -22.1 -5.3 <0.0001
  1. Quality of life components are shown from the ATTAIN study, which compared abatacept plus methotrexate versus placebo plus methotrexate in patients with rheumatoid arthritis who were refractory to tumor necrosis factor-α inhibition. ATTAIN, Abatacept Trial in Treatment of Anti-TNF Inadequate Responders; MOS, medical outcome study; VAS, visual analog score.
\